Cirstea, Diana

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 616

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood

Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments

Cited by 432

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 159

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsVitamin C and Antioxidants Research

Cited by 109

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Fabre, C., Mimura, N., Bobb, K., Kong, S.-Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., et al. (2012) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 82